CANCER:

Uterine Corpus Leiomyosarcoma

News alerts, weekly reports and conference planners

Related cancers:

ATRX mutation	Uterine Corpus Leiomyosarcoma	ATRX mutation	Uterine Corpus Leiomyosarcoma	BAY 1895344 Sensitive: D – Preclinical IGCS 2022 - 2 weeks (New D) BAY 1895344 Sensitive : D IGCS 2022 - 2wk	BAY 1895344 Sensitive: D – Preclinical IGCS 2022 - 2 weeks BAY 1895344 Sensitive : D IGCS 2022 - 2 weeks - (New D)
No biomarker	Uterine Corpus Leiomyosarcoma	No biomarker	Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2	Aromatase inhibitor Sensitive: A2 - Guideline Aromatase inhibitor Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2	medroxyprogesterone Sensitive: A2 - Guideline medroxyprogesterone Sensitive : A2
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2	megestrol Sensitive: A2 - Guideline megestrol Sensitive : A2
AKT1 E17K	Uterine Corpus Leiomyosarcoma	AKT1 E17K	Uterine Corpus Leiomyosarcoma	AZD5363 Sensitive: C3 – Early Trials AZD5363 Sensitive : C3	AZD5363 Sensitive: C3 – Early Trials AZD5363 Sensitive : C3
CD70 expression	Uterine Corpus Leiomyosarcoma	CD70 expression	Uterine Corpus Leiomyosarcoma	ARX305 Sensitive: C3 – Early Trials ARX305 Sensitive : C3	ARX305 Sensitive: C3 – Early Trials ARX305 Sensitive : C3
ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	ER positive + PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PGR positive	Uterine Corpus Leiomyosarcoma	PGR positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
ER positive	Uterine Corpus Leiomyosarcoma	ER positive	Uterine Corpus Leiomyosarcoma	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3	anastrozole Sensitive: C3 – Early Trials anastrozole Sensitive : C3
PALB2 deletion	Uterine Corpus Leiomyosarcoma	PALB2 deletion	Uterine Corpus Leiomyosarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
RAD51B deletion	Uterine Corpus Leiomyosarcoma	RAD51B deletion	Uterine Corpus Leiomyosarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4	crizotinib Resistant: C4 – Case Studies crizotinib Resistant : C4
FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	FN1-ALK fusion	Uterine Corpus Leiomyosarcoma	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4	pazopanib Resistant: C4 – Case Studies pazopanib Resistant : C4
BRCA2 mutation	Uterine Corpus Leiomyosarcoma	BRCA2 mutation	Uterine Corpus Leiomyosarcoma	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D	PARP inhibitor Sensitive: D – Preclinical PARP inhibitor Sensitive : D

Uterine Corpus Leiomyosarcoma

Associations(20)

Associations
(20)